Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro.
Sci Rep · 2015
Last updated 2026-05-28In lab tests, a GLP-1 drug called Exendin-4 (Ex-4) helped bone marrow stem cells grow faster, move more easily, and survive longer. When exposed to harmful conditions, Ex-4 protected the cells by reducing damage and balancing proteins that control cell death, with effects linked to a specific cell pathway (PI3K/Akt).
AI summary of the abstract below.
| Journal | Sci Rep, 2015 |
|---|---|
| Citations | 97 |
| Relative citation ratio | 3.84 |
| NIH percentile | 89 |
| Molecules | — |
Abstract
Mesenchymal stem cells (MSC) are regarded as an attractive source of therapeutic stem cells for myocardial infarction. However, their limited self-renewal capacity, low migration capacity and poor viability after transplantation hamper the clinical use of MSC; thus, a strategy to enhance the biological functions of MSC is required. Exendin-4 (Ex-4), a glucagon-like peptide-1 receptor agonist, exerts cell-protective effects on many types of cells. However, little information is available regarding the influence of Ex-4 on MSC. In our study, MSC were isolated from bone marrow and cultured in vitro. After treatment with Ex-4, MSC displayed a higher proliferative capacity, increased C-X-C motif receptor 4 (CXCR4) expression and an enhanced migration response. Moreover, in H2O2-induced apoptosis, Ex-4 preserved mitochondrial function through scavenging ROS and balancing the expression of anti- and pro-apoptotic proteins, leading to the inhibition of the mitochondria-dependent cell death pathways and increased cell survival. Moreover, higher phospho-Akt (p-Akt) expression was observed after Ex-4 intervention. However, blockade of the PI3K/Akt pathway with inhibitors suppressed the above cytoprotective effects of Ex-4, suggesting that the PI3K/Akt pathway is partly responsible for Ex-4-mediated MSC growth, mobilization and survival. These findings provide an attractive method of maximizing the effectiveness of MSC-based therapies in clinical applications.
Verbatim abstract via PubMed 26250571 ↗